Limited Coverage Drugs – risedronate

Generic  name Strength, form Special Authority criteria Approval period
risedronate 5 mg tablet or
35 mg tablet

Clinical or radiographically documented fracture due to osteoporosis


Glucocorticoid-induced osteoporosis in patients who are receiving or expected to receive the equivalent dose of 7.5 mg or more of prednisone per day for 90 or more consecutive days




1 year

risedronate 30 mg Diagnosis of Paget's disease Indefinite

 Practitioner exemptions

  • None

Special notes

  • Patients who meet the above criteria for osteoporosis for risedronate automatically receive coverage for both alendronate and risedronate.
  • Clinical fracture is defined as a symptomatic (painful) fracture.
  • Radiographically documented fracture is defined as a fracture identified by x-ray (e.g., vertebral compression fracture). This may be asymptomatic.
  • Coverage is intended for patients taking glucocorticoids with significant systemic absorption only (i.e., by oral or parenteral routes).

Special Authority requests